Important Safety Information:
CONTRAINDICATIONS: ELOCTATE is contraindicated in patients who have had life-threatening hypersensitivity reactions to ELOCTATE or its excipients.
WARNINGS AND PRECAUTIONS: Hypersensitivity reactions have been reported with ELOCTATE. Allergic-type hypersensitivity reactions, including anaphylaxis, have been reported with Factor VIII replacement products.Full Important Safety Information
Acute Joint Bleed
>30% of patients with severe hemophilia in their 20s and 30s reported more than 5 bleeds in a 6-month period2*Learn about the ELOCTATE mechanism of action
*Result extracted from a descriptive analysis of the impact of changes in hemophilia care on the outcomes of 4899 men with severe hemophilia A or B living in the United States, based on prospectively collected data in the Universal Data Collection database between May 1998 and September 2011.2